Drug
Trabectedin clinical trials
Also written Yondelis, ET-743 and ecteinascidin 743.
- studies test it
- 72
- open now
- 10
- in phase 3
- 13
- first study started
- 1996
Keep track of what changes. Save the Trabectedin studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
71 studies that test it; most in 2011 (9)
| Year | Studies |
|---|---|
| 1996 | 1 |
| 1999 | 1 |
| 2000 | 1 |
| 2001 | 2 |
| 2002 | 4 |
| 2003 | 1 |
| 2004 | 1 |
| 2005 | 1 |
| 2007 | 3 |
| 2008 | 4 |
| 2009 | 1 |
| 2010 | 3 |
| 2011 | 9 |
| 2012 | 1 |
| 2013 | 3 |
| 2014 | 5 |
| 2015 | 3 |
| 2016 | 1 |
| 2017 | 5 |
| 2018 | 6 |
| 2019 | 4 |
| 2020 | 3 |
| 2021 | 4 |
| 2022 | 1 |
| 2025 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 14
- Phase 2
- 49
- Phase 3
- 13
- Phase 4
- 1
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
- Sarcoma
- 22
Who runs them
Industry 17 · Other 55
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (10) · Italian Sarcoma Group (8) · Mario Negri Institute for Pharmacological Research (5) · European Organisation for Research and Treatment of Cancer - EORTC (5) · Grupo Espanol de Investigacion en Sarcomas (4) · Janssen Research & Development, LLC (4) · Gustave Roussy, Cancer Campus, Grand Paris (3) · M.D. Anderson Cancer Center (3)
Often tested with
Tested in the same studies.
Doxorubicin (5) · Olaparib (4) · Gemcitabine (3) · Nivolumab (3) · Olaratumab (2) · Bevacizumab (2) · Carboplatin (2) · Ipilimumab (2)
Studies
Open first, then newest update. How each study uses Trabectedin is read from its arms, and is right about nine times in ten.
Testing it · 72
- Phase II Decentralized Pragmatic Trial of Adjuvant Doxorubicin - Trabectedin Chemotherapy in uLMSRecruitingPhase 2M.D. Anderson Cancer CenterNCT07076186Written as Trabectedin
- Interest of Post-operative Chemotherapy in Patients With Localised Uterine Leiomyosarcoma Suspected of Having a High Risk of Recurrence Based on a Biological Test Performed on the TumourRecruitingPhase 2UNICANCERNCT06524583Written as Trabectedin
- A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue SarcomasRecruitingPhase 1M.D. Anderson Cancer CenterNCT07444619Written as Trabectedin
- Study on Trabectedin in Advanced Rearranged Mesenchymal ChondrosarcomaRecruitingPhase 2Italian Sarcoma GroupNCT04305548Written as Trabectedin
- Trial in Patients With Metastatic or Locally Advanced LeiomyosarcomaRecruitingPhase 2Italian Sarcoma GroupNCT04383119Written as Trabectedin
- Talimogene Laherparepvec, Nivolumab and Trabectedin for SarcomaRecruitingPhase 2Sarcoma Oncology Research Center, LLCNCT03886311Written as Trabectedin 0.25 MG/1 VIAL Intravenous Powder for Solution
- SAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue SarcomaRecruitingPhase 1/2Sarcoma Oncology Research Center, LLCNCT03138161Written as Trabectedin
- Metronomic Trabectedin, Gemcitabine, and Dacarbazine for Soft Tissue SarcomaRecruitingPhase 2Sarcoma Oncology Research Center, LLCNCT04535271Written as Trabectedin
- Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma PatientsRecruitingPhase 1/2Grupo Espanol de Investigacion en SarcomasNCT02275286Written as Trabectedin
- Multicohort Trial of Trabectedin and Low-dose Radiation Therapy in Advanced/Metastatic SarcomasRecruitingPhase 2Grupo Espanol de Investigacion en SarcomasNCT05131386Written as Trabectedin
- Trial Comparing Trabectedin to the Best Supportive Care in Patients With SarcomaCompletedPhase 3Gustave Roussy, Cancer Campus, Grand ParisNCT02672527Written as Trabectedin
- Continuing vs Intermittent Trabectedin in Patients With Advanced Soft Tissue SarcomaCompletedPhase 2Centre Oscar LambretNCT01303094Written as Trabectedin
- Prospective Identification of Predictive Biomarkers of Trabectedin Efficacy in Non-L Soft-tissue Sarcoma PatientsCompletedNot applicableInstitut BergoniéNCT04008238Written as Trabectedin
- Study on Trabectedin in Combination With Pioglitazone in Patients Myxoid Liposarcomas With Stable Disease After T Alone.CompletedPhase 2Mario Negri Institute for Pharmacological ResearchNCT04794127Written as Trabectedin
- Targeting Microenvironment and Cellular Immunity in Sarcomas Weekly Trabectedin Combined With Metronomic CyclophosphamideCompletedPhase 1/2Institut BergoniéNCT02805725Written as Phase 1: Trabectedin
- Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant ChemotherapyCompletedPhase 3Italian Sarcoma GroupNCT01710176Written as trabectedin 1.3 mg/m2
- Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic SarcomaCompletedPhase 2University of Michigan Rogel Cancer CenterNCT04076579Written as Trabectedin
- Trabectedin for Recurrent Grade II/III MeningiomaCompletedPhase 2European Organisation for Research and Treatment of Cancer - EORTCNCT02234050Written as Trabectedin
- QoL-Comparison Between Trabectedin/PLD and Pt-based Therapy in Patients With Pt-sensitive Recurrent Ovarian CancerTerminatedPhase 4North Eastern German Society of Gynaecological OncologyNCT03164980Written as Trabectidin (Yondelis)
- Study With Trabectedin Versus Adriamycin Plus Dacarbazine, in Patients With Advanced Solitary Fibrous TumorCompletedPhase 2Italian Sarcoma GroupNCT03023124Written as Trabectedin
See all 72 studies that test Trabectedin →
Given in every arm · 3 — Trabectedin is usual care beside what is tested
- tTF-NGR Randomized Study - STSRecruitingPhase 3Universität MünsterNCT05597917Written as Trabectedin
- SARC037: A Phase I/II Study to Evaluate the Safety of Trabectedin in Combination With Irinotecan in Ewing Sarcoma PatientsCompletedPhase 1/2Sarcoma Alliance for Research through CollaborationNCT04067115Written as Trabectedin 1 MG [Yondelis]
- A Safety Study Utilizing Yondelis and Doxorubicin in Patients With a Type of Cancer Called Soft Tissue SarcomaCompletedPhase 1Johnson & Johnson Pharmaceutical Research & Development, L.L.C.NCT00102609Written as Trabectedin
As the comparator · 3 — what is tested is compared with Trabectedin
- A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)RecruitingPhase 3Intensity Therapeutics, Inc.NCT06263231Written as Trabectedin
- Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped WorkingActive, not recruitingPhase 2/3National Cancer Institute (NCI)NCT05432791Written as Trabectedin
- Treatment of Milademetan Versus Trabectedin in Patient With Dedifferentiated LiposarcomaTerminatedPhase 3Rain Oncology IncNCT04979442Written as Trabectedin
Codes
What other systems call Trabectedin · ClinicalTrials.gg INT006776
- MeSH (NLM) D000077606TrabectedinConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) ID0YZQ2TCPTRABECTEDINConfirmed FDA, NLM, Wikidata
- RxNorm 1716278Confirmed FDA, Wikidata
- Wikidata Q2637746trabectedinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1691TrabectedinOne source FDA
- DrugBank DB05109One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000077606 | Trabectedin | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | ID0YZQ2TCP | TRABECTEDIN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1716278 | — | Confirmed FDA, Wikidata |
| Wikidata | Q2637746 | trabectedin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1691 | Trabectedin | One source FDA |
| DrugBank | DB05109 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.